The law firm of Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) (“Optimer” or “the Company”), concerning the Company’s proposed acquisition by Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) (“Cubist”). Under the terms of the merger agreement, Optimer shareholders will receive $10.75 in cash for each share of Optimer common stock they own. Optimer shareholders will also receive one Contingent Value Right of up to $5.00 per share should certain net sales milestones of the drug DIFICID be reached. The total transaction is valued at approximately $801 million. At least one analyst has set a target price of $25.00 for Optimer shares.
The investigation is focused on the potential unfairness of the consideration to shareholders, the process by which Optimer’s Board of Directors considered the transaction, and potential conflicts of interest among the Company’s Board members.
If you are interested in discussing your rights as an Optimer shareholder, or have information relating to this investigation, please contact Finkelstein Thompson’s Washington, DC offices at (202)-337-8000 or by email at email@example.com.
Finkelstein Thompson LLP has spent over three decades delivering outstanding representation to institutional and individual clients in financial litigation, and has been appointed as lead or co-counsel in dozens of shareholder class actions. Indeed, the firm has served in leadership roles in cases that have recovered over $1 billion for investors and consumers.To learn more about Finkelstein Thompson LLP, please visit our website at www.finkelsteinthompson.com. Attorney advising. Prior results do not guarantee similar outcomes.